Kornimate/medical-research-clean huggingface dataset:
evaluation of the clinical performance of apneal®, a medical device on smartphone, for sleep apnea-hypopnea syndrome diagnosis.

Conditions: Sleep Apnea Syndromes

Summary: the goal of this clinical trial is to test the ability of the apneal application in diagnosing sleep apnea in adult patients. participants will be asked to wear the apneal device during their fulll-night sleep test (polysomnography, the gold standard for sleep apnea)


Eligibility criteria:
inclusion criteria: * individuals, men or women, aged over 18 and with no upper age limit; * individuals for whom psg is indicated as part of routine care, regardless of indication. * individuals willing and able to comply with study requirements; * individuals with a declared total sleep time of at least 6 hours, as recommended by aasm for psg analysis. * individuals affiliated to social security or beneficiary of such a scheme if applicable according to the local regulation ; * voluntary individuals who have provided oral and written consent after being informed by the research investigator. exclusion criteria: * individuals with active implantable medical devices (e.g. electronic heart implant, electrical neurophysiological stimulator...); * individuals with mechanical heart valves; * individuals with chest deformity preventing the phone to be correctly placed on the chest * individuals with uncontrolled psychiatric conditions impairing their ability to fully consent to the study * individuals suffering from epilepsy or an associated disorder; * individuals suffering from a moderate to severe valvular disease; * individuals under cpap treatment during the participation. * individuals suffering from a nervous system disorder that causes unintended or uncontrollable movements, other than periodic leg movement syndrome and restless leg syndrome. * refusal to participate in the study at any time during the clinical investigation; * individuals in period of exclusion from another protocol or currently participating in another interventional research study; * individuals not able to understand and speak the official language of the research center; * vulnerable individuals according to local legislation
ozonated olive oil and low-level laser therapy in tmd treatment

Conditions: TMD

Summary: the aim of the present study was to determine the efficacy of ozonated olive oil and low-level laser therapy (lllt) in treating pain in individuals with tmd. in this prospective, randomized, split-mouth, double-blind study, two different treatment methods were applied to the patients.

two different treatment methods were applied to the patients. group 1 (study group, one side of the same patient): topical ozonated olive oil + lllt; group 2 (the other side of the same patient): olive oil with topical ozone + lllt (not activated). the ozonated olive oil was applied topically three times a day for four weeks, the lllt was applied noncontact at a distance of 1 cm, and patients attended three sessions per week for four weeks. before starting treatment, and after 6 sessions of laser therapy, the patients were evaluated. (2 weeks), after 12 laser sessions (1 month), and 3 months after the first session.

Eligibility criteria:
inclusion criteria: 1. individuals aged 18 and over, 2. individuals should be literate so that they can evaluate the consent form themselves, 3. individuals with no restrictions to the use of any medication to be prescribed during the study, 4. individuals who have not been treated for temporomandibular joint disease in the past 3 months, 5. individuals who have not used any medication for the past two weeks, 6. individuals who will participate in the study must be residing in the province of van so that their regular records can be obtained, 7. individuals without systemic disease, 8. individuals with chronic pain, (pain that has been ongoing and lasted longer than six months), 9. individuals with bilateral pain complaints, 10. individuals without missing teeth, 11. individuals without open bite and/or crossbite, exclusion criteria: 1. individuals with internal disorders and/or inflammatory joint disorders and/or joint's sound, 25 2. individuals who have undergone interventional or surgical procedures on the temporomandibular joint, 3. individuals with temporomandibular joint pathology, 4. individuals with the possibility of either being pregnant, are pregnant or lactating, 5. individuals who will not attend postoperative check-ups, 6. individuals using drugs other than those recommended, 7. individuals who are allergic to any of the drugs and materials to be used throughout the study, 8. individuals with contraindications to ozone or laser therapy.
tobacco cessation tailored to patients living with hiv (plwh) in brazil

Conditions: HIV Infections; Tobacco Use Cessation

Summary: the overall goal of this feasibility study is to make adaptations to these evidence-based approaches in collaboration with plwh and health care providers working with this population, and develop, implement, and evaluate the feasibility and scalability of a theory-based, culturally relevant tobacco cessation intervention for plwh receiving care through the public health system in a southern town in brazil (londrina). this proposal will focus on the intervention development, pretesting, and feasibility testing. the primary outcome will be a 7-day point prevalence abstinence (defined as no tobacco use in the past 7 days and verified through measurement of salivary cotinine and exhaled carbon monoxide levels) at 6-month follow-up. we will also conduct detailed treatment fidelity and scalability assessments (acceptability, feasibility, potential reach and adoption, alignment with the strategic context) to inform a full-scale efficacy trial.

this study aims at developing and examining feasibility and scalability of a theory-based, culturally relevant tobacco cessation intervention for plwh receiving care through the public health system in a southern town in brazil. it consists of three phases: formative assessments with patients and health care providers to inform relevant components of the intervention, pretesting of the intervention components, and pilot testing of the intervention (feasibility).

Eligibility criteria:
inclusion criteria: * plwh (that is, patients with a confirmed hiv diagnosis) receiving care at the reference center in londrina * 18 years of age and older; (c) smoke at least 5 cigarettes (industrialized or hand-rolled) per day smoked within the past seven days. * no intent to move from the area served by reference center in londrina within the next 12 months. exclusion criteria: * history of hypertension * history of angina * history of asthma * on medication for depression.

Keywords: hiv, tobacco cessation
one touch® verio®iq european clinical outcomes study

Conditions: Diabetes

Summary: evaluation of the clinical benefits of one touch verioiq system.

evaluation of the clinical benefits of the one touch verioiq system. the system contains pattern alert technology and comes with educational material (pattern guide) which provides additional support and insights to patients and health care providers to help them make more informed decisions during blood glucose management.

Eligibility criteria:
inclusion criteria: * male or female at least 18 to 80 years old * ada guidelines for fpg and ppg appropriate * a1c greater or equal to 8.0% and less than or equal to 10.5% * lab a1c greater than or equal to 8.0% in the last 6-12mths * diagnosed with type 1 or 2 in at least last 1 year * on stable dose of oads for at least 3mths prior to screening * willingness to test 7 bgm tests per day * willing to remain on same therapy as baseline (mdi) for duration of study exclusion criteria: * unlikely to be compliant to study procedures * has or has currently used one touch verioiq * is on fixed doses of insulin for mdi therapy

Keywords: blood glucose monitor pattern management pattern guide education
a clinical trial of csl's 2009 h1n1 influenza vaccine (csl425) in a healthy pediatric population in the usa

Conditions: Influenza

Summary: the purpose of this study is to evaluate the immunogenicity and safety profile of csl425 (csl's 2009 h1n1 influenza vaccine) in a healthy pediatric population.


Eligibility criteria:
inclusion criteria: * male or female aged \>= 6 months to \< 9 years at the time of the first study vaccination. * for children \< 3 years of age at the time of first vaccination, born at or after 36 weeks gestation. exclusion criteria: * known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of the study vaccine
dafilon® suture material in patients undergoing ophthalmic surgery

Conditions: Eye Diseases

Summary: this is an observational, retrospective postmarket clinical follow-up study and includes all patients who underwent any ophthalmic surgery using dafilon® suture in the selected centres between 2018 and 2020, therefore no sample size can be given but the planned sample size shall be at least 200 eyes (around 100 patients depending on the number of operated eyes per patient) to conduct meaningful subgroup analysis.


Eligibility criteria:
inclusion criteria: * patient operated between 2018 - 2020 undergoing any ophthalmic surgery using dafilon® suture material (dafilon® usp (united states pharmacopeia) sizes from 8/0 to 11/0) at the participating hospital exclusion criteria: * no exclusion criteria have been set

Keywords: ophthalmologic surgery
epo906 therapy in patients with advanced kidney cancer

Conditions: Kidney Neoplasms

Summary: this study will examine whether the investigational drug epo906, given by intravenous infusion (iv directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.


Eligibility criteria:
inclusion criteria: the following patients may be eligible for this study: * histologically or cytologically documented evidence of epithelial renal cell carcinoma with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the radiation) * patients must have had a prior nephrectomy * must have a life expectancy of greater than three (3) months * patients who have had 0-1 prior cytokine treatment regimen (i.e. il-2, ifn-?) or relapsed less than one year after such treatment may be eligible. exclusion criteria: the following patients are not eligible for this study: * patients who have received more than one (1) prior cytokine regimen (i.e. il-2, ifn?) or relapsed more than one year after receiving such treatment are not eligible * patients who have had any prior chemotherapy (including a combination therapy) * patients with symptomatic cns metastases or leptomeningeal involvement * patients with any peripheral neuropathy or unresolved diarrhea greater than grade 1 * patients with severe cardiac insufficiency * patients taking coumadin or other warfarin-containing agents with the exception of low dose coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports * history of another malignancy within 3 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ * patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae * hiv+ patients * pregnant or lactating females.

Keywords: kidney cancer renal cancer cancer tumor tumour neoplasm carcinoma clear cell sarcomatoid papillary medullary collecting duct chromophobe intravenous epothilone
dapagliflozin vs empagliflozin on flow mediated dilation in type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: type 2 diabetes mellitus (t2dm) is a considered one of the main global health challenges; the vascular endothelium plays an important role in vascular dysfunction in dm; hyperglycemia induced by it is recognized as the main factor for the development of vascular complications of the disease, secondary to a reduction in nitric oxide production; "flow-mediated dilation" is the most commonly used technique for the evaluation of endothelial function, being the non-invasive method most widely used. it has been reported that with the use of sglt2 inhibitors the development of cardiovascular complications in patients with t2dm is a decrease, as well the arterial stiffness, endothelial dysfunction and increasing on the shear stress and blood viscosity; and experimentally.

the objective of this study, is to evaluate the acute effect of the administration of dapagliflozin in comparison with the administration of empagliflozin on endothelial disfunction in individuals with t2dm; we will conduct a double-blind, randomized, placebo-controlled, trial with 3 groups, each group of 24 male and female patients, between 40-65 years of age with t2dm, without hypertension, treated with insulins or thiazide diuretics. randomization will determine who will receive the intervention during 7-days trial (empagliflozin 25 mg 1 time daily 5 minutes or dapagliflozin 10 mg before the first bite of each meal or approved placebo capsules), the patients will also continue with their usual treatment. the clinical findings and laboratory test and laboratory test include a metabolic profile and biosafety, baseline and at 7 days. body weight, body fat, body mass index (bmi) and blood pressure will be determined during the initial and final visit, likewise, hemodynamics parameters of endothelial disfunction by flow mediate dilation with a high-resolution unex ef38g® ultrasound. adverse events to treatment will be documented. statistical analysis: mann-whitney u test and wilcoxon exact test. a p \<0.05 will be considered statistically significant.

Eligibility criteria:
inclusion criteria: * diagnosis of t2dm * hba1c \> 7 y \< 10 * bmi 25 - 34.9 kg/m2 * signature of consent under information exclusion criteria: * hypertension * treated with insulin and / or loop diuretics and thiazides * t1dm * hypotension * with any autoimmune disease * liver disease * women who do not have a safe method of contraception * women who are taking oral contraceptives or under treatment with hormone replacement therapy * woman pregnant or breastfeeding * untreated thyroid disease * patients with a cardiovascular disease that contraindicates the use of this pharmacological class * glomerular filtration rate \<60ml/min (cockcroft-gault)

Keywords: dapagliflozin empagliflozin fmd t2dm endothelial disfunction
assuring and defining outcomes through procedural training using a proctorship model that collects patient outcomes a single-arm, case-series to determine the feasibility of safe skills transfer for laparoscopic ventral hernia repair utilizing a hands-on proctorship model.

Conditions: Hernia

Summary: the objective of the project adopt- ventral hernia case-series is to collect clinical outcome data following the completion of a hands-on proctorship training model in laparoscopic ventral hernia repair.

the adopt- ventral hernia project is designed as a prospective, single arm, case series. the proctor will select a limited number of licensed surgeon trainees (up to 5) as agreed upon by covidien and the proctor. the proctor will then train through clinical immersions, hands on proctorship and video training for proper technique on minimally invasive surgical (mis) repair of ventral hernia. after the training, the data will be collected on the trainee's next 10 mis ventral hernia repair cases, pending subject consent to collect data. procedural and post-operative details will be captured for each of these subjects who have undergone the laparoscopic ventral hernia repair.

Eligibility criteria:
inclusion criteria: * determined by surgeon's standard of care exclusion criteria: * determined by surgeon's standard of care
improving adherence healthy lifestyle with a smartphone application based after surgery in cancer patients

Conditions: Secondary Prevention

Summary: background: the cancer-related lymphedema (bcrl) is the abnormal accumulation of fluid in the lymphatic system and can develop immediately after surgery / radiotherapy of breast cancer, or may appear months later. in the literature there are numerous educational recommendations to avoid the appearance bcrl, but there is a lack of adherence to these recommendations. with the increase of mobile technologies among adults, the mobile devices can be an effective method to meet their education. objective: to determine the effectiveness of therapeutic adherence a brief educational intervention through a smartphone-based application in the prevention of lymphedema in women with mastectomies. method: 100 women survivors of breast cancer will be randomized to a group that will receive lymphedema prevention education and an app specific for better adhesion compared to the control group will receive education only. they will be monitored for 28 weeks by specific measures of lymphedema onset, volume and perimeter arm and hand strength lymphedema disability questionnaire and other measures of fatigue, quality of life and mood related to cancer. discussion: the lack of adherence to health education is the main cause of failure in maintaining these brief educational interventions, whether the program is beneficial, it could be successfully implemented in clinical practice.


Eligibility criteria:
women diagnosed with breast cancer, including the via clinic (11) breast cancer at the hospital costa del sol, marbella, spain. inclusion criteria : * be over 18 years * with own smartphone telephony server and mobile internet. exclusion criteria : * reading problems, psychological problems, who can not read spanish * unwilling to participate in the study. it also takes into account the severity of the disease, dividing criteria, conservative surgery, mastectomy, with or without lymphadenectomy, sentinel node.

Keywords: lymphedema, prevention, ehealth, cancer
micronutrients and health in adult chinese

Conditions: Dysglycemia; Dyslipidemia

Summary: adult subjects were recruited from a health examination center. their fasting blood samples were collected for laboratory analyses of multiple measures including mineral, glucose, lipids, etc.


Eligibility criteria:
inclusion criteria: * adult volunteer * han population * living in shenzhen city for \> 2 y exclusion criteria: * caught by organic diseases * in pregnancy
the retroclavicular approach for regional anesthesia of the upper limb in obese patients

Conditions: Overweight

Summary: the goal of this study is to determine the success rate of the retroclavicular approach for the anesthesia of the upper limb in the obese patient population (bmi ≥ 30 kg/m2)

classic infraclavicular approach of the brachial plexus involves a needle puncture below the clavicle and advancing the needle with a 45-60 degree angle from cephalad to caudad. the aim is to advanced the block needle posterior to the axillary artery and to deposit the local anesthetic at that point, near the posterior cord. a "u" shaped spread around the artery should ensure distribution around all three cords. ultrasound guidance is highly recommended and neurostimulation is optional. the retroclavicular approach is a variant to this classical technique. ultrasound probe is positioned initially below the clavicle in a manner similar to the classic approach but is then rotated in a clockwise fashion (right arm) or counter-clockwise fashion (left arm) for about 25-35 degrees. the puncture site is just behind the clavicle at the most lateral point available. if initial entry point is optimal, needle direction is then parallel to ultrasound probe. the final aim and position of block needle is identical to classical approach. entry point ensures a parallel alignment of the needle and the ultrasound beam, thus enabling almost perfect visualization of both artery, cords and block needle. this is turn optimizes safety, rapidity of technique, efficiency and efficacy. it is recognized that regional anesthesia is more difficult to perform in obese patients. anatomic landmarks are harder to localize in this population and ultrasound guidance is more difficult because of the attenuation of the ultrasound beam by adipose tissue. the complication rate of regional techniques is also reported to be higher in the obese patient population. since the retroclavicular variant of the infraclavicular approach for the anesthesia of the brachial plexus offers a better needle visualisation, we believe that this technique can be used successfully in the obese patient population with a low complication rate.

Eligibility criteria:
inclusion criteria: * elective or urgent surgery of the hand, wrist or forearm * 18 years and older * ability to consent * american society of anesthesiologists class 1 to 3 * bmi ≥ 30 kg/m2 exclusion criteria: * infection at the site of infection * abnormal anatomy at the site of infection * coagulopathy * severe pulmonary disease * preexisting neurological symptom(s) in the operated arm * pregnant patients * patients weighing less than 50 kg * allergy to amide type local anesthetics

Keywords: infraclavicular block brachial plexus retroclavicular approach complications of retroclavicular approach success of retroclavicular approach obese patients obesity and anesthesia
the influencing factors of vancomycin trough level and the rate achieving the target trough level

Conditions: Vancomycin

Summary: the aim of this study was to assess factors that may influence vancomycin trough level and the rate achieving the target trough level in critically ill patients.

this retrospective observational study included adult patients treated with intravenous vancomycin in intensive care unit of zhongda hospital from january 2015 to december 2017. vancomycin dose was based on international consensus and adjusted according to estimated glomerular filtration rate (egfr) calculated by the cockcroft-gault equation. vancomycin trough level (vtl) was retained at steady state (after the third dose). linear regression was performed to determine the correlation between factors prior to the first vancomycin dose and vtl. distribution of vtl and percentage of patients achieving the target trough level (15-20mg/l) was observed in different renal function.

Eligibility criteria:
inclusion criteria: * adult icu patients (age≥18 years) treated with intravenous vancomycin were included exclusion criteria: * chronic renal dysfunction and acute renal injury patients treated with renal replacement therapy * vtl was not retained at steady-state * vancomycin treatment time≤48h * vancomycin dose did not meet study definitions * palliative care